Background : Japanese physicians tend to empirically maintain lower-intensity prothrombin time-international normalized ratios (PT-INR) of 1.6-2.6 for most non-valvular atrial fibrillation (NVAF)patients taking warfarin. However, the optimal anticoagulant intensity in Japanese patients with low CHADS2(Congestive heart failure, Hypertension, Age B75, Diabetes, Stroke [doubled])scores is not clear. This study aimed to evaluate the clinical outcome and anticoagulant intensity in Japanese NVAF patients aged B65 years with CHADS2 scores of 0-1 and taking warfarin. Methods : We included 382 consecutive NVAF patients aged B 65 years with CHADS2 scores of 0-1, who took warfarin between 2001 and 2006 (median age, 68 years ; 29.8％ women). This study included a median follow-up period of 54 months (1-154 months). The occurrence of thromboembolic events including ischemic stroke, transient ischemic attack and other systemic embolism, as well as major bleeding events were validated through a medical record review. Results : The incidence of thromboembolic and major bleeding events was both 0.9 per 100 patient-year. All thromboembolic events occurred in patients with a PT-INR ＜2.00. The incidence of major bleeding events increased markedly in patients with a PT-INR B3.00. A HAS-BLED(Hypertension, Abnormal renal／liver function, Stroke, Bleeding history or predisposition, Labile INR, Elderly and concomitant Drugs／alcohol)score B3 was a risk for major bleeding(hazard ratio 4.8, 95％ confidence interval 1.6-14.4). A PT-INR of 2.00-2.99 predicted a low incidence of thromboembolic and major bleeding events. Conclusions : Our results showed that a PT-INR of 2.00-2.99 was associated with a low incidence of both thromboembolism and major bleeding in Japanese NVAF patients aged B65 years with CHADS2 score of 0-1 and taking warfarin.
Introduction
Atrial fibrillation (AF) is the most clinically prevalent tachyarrhythmia 1, 2) . AF is a potential risk factor for stroke, and AF-associated strokes are often severe, resulting in disability or death 3−6) . The CHADS2(Congestive heart failure, Hypertension, Age B75, Diabetes, Stroke [doubled］ ) score is simple and is useful for risk stratification of stroke in nonvalvular AF(NVAF) patients 7) . Anticoagulant therapy with an oral anticoagulant (OAC)reduces the risk of AF-related stroke 8) . The vitamin K antagonist(VKA)warfarin was the most commonly used OAC in Japan prior to the availability of non-vitamin K antagonist oral anticoagulants(NOACs), and remains an important OAC for the prevention of stroke in NVAF patients.
Warfarin has a risk of serious bleeding complications and has been indicated for patients with CHADS2 scores B2. Indeed, the AnTicoagulation and Risk Factors in Atrial Fibrillation(ATRIA) study showed that a net clinical benefit of warfarin therapy (balancing ischemic stroke against intracranial hemorrhage)was observed in patients with a CHADS2 score B2 9)
. On the other hand, the bleeding risk is thought to outweigh the benefit of stroke reduction in patients with CHADS2 scores of 0-1.
The J-RHYTHM registry, a multicenter, contemporary, prospective observational study with a 2-year follow-up, which included 7,384 Japanese patients with NVAF, has reported that 50％ of the subjects had CHADS2 scores of 0-1 and that 82％ had taken warfarin 10) . Stroke risk factors also confer an increased risk of bleeding, because some of the risk factors for stroke and bleeding overlap. The presence of these risk factors may increase the risk of the development of a combined stroke. Thus, patients with low CHADS2 scores have a low bleeding risk.
Post-hoc analysis of the Atrial Fibrillation Clopidogrel Trial with Irbesartan for Prevention of Vascular Events(ACTIVE-W) study reported a greater benefit associated with OAC(warfarin) compared with clopidogrel plus aspirin, regardless of whether the patientsʼ baseline CHADS2 score fell in the range of 0 to 1 11) . Recent cohort studies showed that VKA use was associated with a lower stroke rate in patients with CHADS2 score of 1, compared with antiplatelet or no antithrombotic therapy 10, 12, 13) . . The 2012 European Society of Cardiology�ESC�guidelines recommended opportunistic screening for AF prior to the first stroke in patients aged B65 years, and OAC therapy for NVAF patients with a CHA2DS2 -VASc score B2. Moreover, the guidelines recommended that OAC therapy should be considered in patients with a CHA2DS2-VASc score of 1
17�
. The 2013 Japanese guidelines for pharmacotherapy of AF provided a recommendation similar to that of the ESC guidelines for risk stratification and use of OAC
18�
. The Japanese guidelines recommended that use of OAC as primary prevention of stroke is indicated in NVAF patients with a CHADS2 score of 0-1 and a CHA2DS2-VASc B1�and minimum age of 65 years�.
However, the 2013 guidelines for pharmacotherapy of AF in Japan still recommended that patients aged B70 years be maintained at a lower-intensity prothrombin time-international normalized ratio �PT-INR� range �1.6-2.6�
, because a PT-INR ＜1.6 increases the risk of serious ischemic stroke and a PT-INR ＞2.6 increases the risk of serious bleeding complications 19,20� . Recently, the J-RHYTHM registry showed that a PT-INR between 1.6 and 2.6 is optimal in Japanese patients regardless of age 21� . We previously reported that a target PT-INR of 2.0�within the range of 1.5-2.5�was optimal for Japanese NVAF patients aged B70 years with a CHADS2 score B2
22�
. However, few reports have focused on the optimal anticoagulant intensity in Japanese patients with low CHADS2 scores. This study aimed to evaluate the clinical outcome and anticoagulant intensity in Japanese NVAF patients aged B65 years with CHADS2 scores of 0-1 who were taking warfarin.
Methods

Subjects
We retrospectively conducted a cohort study in NVAF patients with CHADS2 scores of 0-1 and aged B65 years who were taking warfarin. To identify patients who were prescribed warfarin and had PT-INR measurements, we first searched automated outpatient accounting databases. Then, we identified patients with a diagnosis of AF by checking their outpatient medical records. We excluded patients with valvular heart disease or concurrent hyperthyroidism, as well as those without risk factors for stroke. Valvular heart disease was defined as moderate or severe mitral stenosis and mild rheumatic mitral stenosis according to angiographic, hemodynamic or echocardiographic results, or a history of valvular surgeries including valvular repair and replacement. We included 382 consecutive NVAF patients with a CHADS2 score of 0-1 who were over 65 years of age between May 2001 and December 2006. The protocol was approved by the institutional review board of Tokyo Womenʼs Medical University.
Clinical characteristics
Data on patient age, sex, traditional risk factors�hypertension, diabetes mellitus, heart failure�, underlying disease and concomitant medications were obtained from medical records and laboratory data. Hypertension was defined as a systolic blood pressure B140 mmHg, a diastolic blood pressure B90 mmHg, or a history of treatment for hypertension. Diabetes mellitus diagnosed by a physician was defined by treatment with hypoglycemic agents or indicated by poor glycemic control �defined as a glycohemoglobin A1c level B6.5％�. Structural heart diseases consisted of the following apparent cardiac disorders : left ventricular �LV� systolic dysfunction and／or marked LV dilatation �unless secondary to severe valve regurgitation� ; LV hypertrophy ; coronary artery disease ; right heart disease with right ventricular dilation of at least moderate severity ; and congenital heart disease. Coronary artery disease was defined based on positive stress test results, coronary angiography demonstrating at least 75％ of stenosis, or coronary spastic angina documented by an acetylcholine provocation test, a history of prior myocardial infarction, or a history of revascularization procedures. Nonischemic cardiomyopathies were defined as ventricular myocardial abnormalities in the absence of coronary artery disease, or valvular, pericardial or congenital heart disease. Heart failure was defined according to the American College of Cardiology／American Heart Association criteria 23� ; the patients in our study were stage C�current or prior symptoms of heart failure� or stage D �refractory heart failure�. LV dysfunction was defined based on an LV ejection fraction C40％ by echocardiography, left ventriculography, or radionuclide angiography. Atrial or mitral regurgitation was diagnosed based on the identification of higher than moderate levels of regurgitation using color-flow Doppler echocardiography.
The CHADS2 score and CHA2DS2-VASc score were used to measure stroke risk. The HAS-BLED score �Hypertension, Abnormal renal／liver function, Stroke, Bleeding history or predisposition, Labile INR, Elderly[B65 years], and concomitant Drugs／alcohol�was used to measure bleeding risk 16,17� .
Follow-up
At each follow-up visit, the warfarin dose was monitored using the PT-INR. The PT assays on individual plasma specimens were performed using Thromborel S® �Sysmex, Kobe, Japan�. In our institution, patients who were taking warfarin were often treated with a target PT-INR of 2.0, and an acceptable range of 1.5-2.5 in practice. The frequency of PT-INR testing ranged from once per week if control needed to be established to every one to three months if the PT-INR was stable. Follow-up data were obtained at routine or extra visits at our institution. The patients were followed until the end of the follow-up period�December 31, 2013�or until the time at which they discontinued warfarin, were referred and transferred to different medical facilities for further warfarin treatment, obtained a CHADS2 score B2, met the exclusion criteria, became lost to follow-up, or died. Information concerning deceased patients was obtained from medical records, family members, the patientsʼ general practitioners and the hospitals to which they had been admitted.
Outcomes
The occurrence of thromboembolic and bleeding events was validated through a medical records review by three investigators �M. N., T. S. and T. N.�. Thromboembolic events included fatal or nonfatal ischemic stroke, transient ischemic attack(TIA), and other systemic embolism. Ischemic stroke was defined as the sudden onset of a new focal neurological deficit lasting more than 24 h, which could not be explained by other causes. TIA was diagnosed when the neurological deficit lasted less than 24 h. Computed tomography or magnetic resonance imaging was performed in all patients. Other systemic embolisms were diagnosed using computed tomography, angiography or thrombectomy, and were based on the absence of underlying atherosclerosis in the affected artery. Major bleeding events were defined as intracranial hemorrhage detected by imaging or surgery, intraocular hemorrhage leading to a substantial loss of vision, and gastrointestinal hemorrhage or other severe hemorrhage that was fatal or required endoscopic hemostasis, surgical intervention, hospital admission, or blood transfusion. For patients who died or were admitted to other hospitals due to these events and were not subsequently observed at our hospital, the information was obtained from the respective hospitals. A neurologist(T. N.)also reconfirmed the diagnosis of stroke, TIAs and intracranial hemorrhages in these patients.
Statistical analysis
Summary data are presented either as the median and range, or as the number of patients. PT-INR obtained at routine or extra visits at our institution were analyzed. Time in the therapeutic range (TTR)was calculated using the Rosendaal linear interpolation method 24) , which is a linear interpolation of consecutive PT-INR for calculating the percentage of time that the PT-INR is below, within or above the target therapeutic range(in this study, low intensity＝1.50 to 2.49, and high intensity＝2.00 to 2.99). We calculated the incidence (per 100 patient-year) of thromboembolic and major bleeding events. The event rates were compared between individual groups using the chi-square test. The incidence(per patient-year)of thromboembolism and major bleeding events with appropriate 95％ CI were calculated in relation to the CHADS2 scores of 0 and 1 and the CHA2DS2-VASc scores of 1, 2, 3 and 4. We analyzed the relationship between thromboembolic events and stroke risk factors including female gender, prior stroke／TIA, heart failure, hypertension, diabetes and coronary artery disease using the Cox proportional hazards model for multivariate analysis. We also analyzed the relationship between major bleeding and female gender, renal failure, liver injury, concomitant antiplatelet drug use, labile PT-INR, uncontrolled hypertension and prior bleeding event by the same method. Subgroup analyses using the chi-square test were pre-specified for a HAS-BLED bleeding risk score of 1-2 or B3 and concomitant antiplatelet drug use(0 or B1).
Mean PT-INR before and immediately after the events were considered to be associated with the events. We regarded the mean PT-INR for the period between two measurements as representative of that period. Subsequently, the person-time for each PT-INR was summed over all measurements for all patients. The incidence (per patient-years) of thromboembolic and major bleeding events with appropriate 95％ CI were calculated for PT-INR ＜1.50, 1.50-1.99, 2.00-2.49, 2.50-2.99 and B3.00. P values ＜0.05 were considered to be significant. Data analyses were performed using the SPSS statistical software (version 11.01, SPSS Inc., Chicago, Illinois). 
Results
Patient characteristics
The patientsʼ baseline characteristics are shown in Table 1 . The cohort median age was 68 years �range 65-82 years), and 29.8％ were women. Of the 382 patients studied, 38.5％ had hypertension, 8.9％ had diabetes mellitus, 9.2％ had heart failure, and 40.6％ had structural heart disease. The mean TTR was 70％ for low-intensity PT-INR�1.50-2.49)and 36％ for high-intensity PT-INR�2.00-2.99).
During the study period, 21 patients�5.5％)died, 35 patients �9.2％) discontinued warfarin therapy, 97 patients �25.4％) were referred and transferred to different medical facilities for further warfarin treatment, and 143 patients �37.4％) were censored �128 patients obtained CHADS2 scores of 2 and 15 patients met the exclusion criteria). Eleven patients�2.9％)were lost to follow-up because they did not visit our hospital and provided no explanation.
Thromboembolic and bleeding events
During a median follow-up period of 54 months �1-154 months), 15 patients experienced thromboembolic events�0.9 per 100 patient-year)and 15 patients experienced major bleeding events �0.9 per 100 patient-year). Thromboembolic events comprised fatal ischemic stroke�1 patient), non-fatal ischemic stroke�12 patients), TIA�1 patient)and systemic embolism�1 patient). Major bleeding events comprised fatal intracranial hemorrhage �1 patient), non-fatal intracranial hemorrhage �5 patients)and gastrointestinal hemorrhage�9 patients).
The incidence of thromboembolic and major bleeding events was highest in patients with a CHA2DS2-VASc score 4�Table 2). In a multivariate analysis, prior bleeding event was an independent predictor of major bleeding but no other thromboembolic or bleeding risk factor was found to be significant in our patients taking warfarin. The hazard ratio for major bleeding events was higher in patients with a HAS-BLED score B3 compared with patients with a HAS-BLED score of 1-2�Table 3). Concomitant antiplatelet drug use was not significantly associated with an increased incidence of major bleeding. However, major bleeding occurred in 4 patients with concomitant antiplatelet drug use and a PT-INR C2.00.
Intensity of PT-INR and rates of thromboembolic and bleeding events
All 15 thromboembolic events occurred in patients with a PT-INR ＜2.00, whereas the rate of thromboembolic events was highest in patients with a PT-INR ＜1.50 �Table 4). Among these 15 patients, 7 patients were B70 years of age. Of the 15 major bleeding events, 6 occurred in patients with a PT-INR B 3.00, and the incidence of major bleeding events increased markedly at a PT-INR B3.00 �Table 4). Among these 15 patients, 9 patients were B70 years of age. Table 2 Incidence（per patient-year）of thromboembolism and major bleeding events in relation to CHADS2 score and CHA2DS2-VASc score 
Discussion
Our study in Japanese NVAF patients aged B65 years of age with CHADS2 scores of 0-1 who were taking warfarin revealed the following findings : 1)the crude risk of thromboembolic and major bleeding events was both 0.9 per 100 patient-year, ; 2)a high incidence of thromboembolic events was observed in patients with a CHA2DS2-VASc score 4 ; 3)the hazard ratio for major bleeding was higher in patients with a HAS-BLED score B3 compared with those with a score ＜3 ; and 4)PT-INR 2.0-3.0 was associated with a lower incidence of thromboembolic and major bleeding events.
In general, the annual stroke rates of patients with CHADS2 scores of 0 and 1 are known to be 1.9％(95％ CI 1.2-3.0)and 2.8％(95％ CI 2.0-3.8), respectively, based on the report in 2001 from the National Registry of Atrial Fibrillation 25) . Data from the Euro Heart Survey on Atrial Fibrillation showed that the annual thromboembolism rates of patients with CHADS2 score of 0 and 1 were 1.4％ and 1.9％, respectively 26) . In Japan, Inoue et al 27) reported that the annual thromboembolism rates of patients with CHADS2 scores of 0 and 1 were 0.6％ and 2.5％, respectively. Two studies focused on AF patients with a CHADS2 score of 1 showed a substantial reduction in stroke in patients taking VKA compared with patients taking antiplatelet drug or no OAC, although there was a tendency of increased bleeding 12, 13) . Recently, the CHA2DS2-VASc score was reported to be inadequate for risk stratification among patients with low CHADS2 scores, because the annual stroke rate was nearly 2％ for patients with a CHADS2 score of 0-1 16, 26) . Annual stroke rates in Western patients with CHA2DS2-VASc scores of 1, 2, 3 and 4 were 1.3％, 2.2％, 3.2％ and 4.0％, respectively 16) ; these rates were similar in Asian patients 28) . Although we were not able to perform a direct comparison, our results showed a low incidence of stroke in patients who were taking warfarin regardless of CHADS2 or CHA2DS2 -VASc scores. A recent assessment of bleeding risk using the HAS-BLED score has shown that this score is useful for the management of OAC in AF patients, and that a score B3 indicates a high risk 16, 17) . Our results showed that patients with a high HAS-BLED score(B3) were more likely to have major bleeding. One-third of our patients received warfarin plus antiplatelet therapy. Among these patients, 4 out of 5 patients who experienced major bleeding had a PT-INR ＜2.00 when the bleeding occurred. Thus, warfarin combined with antiplatelet drugs such as aspirin may be associated with an increased risk of bleeding even in NVAF patients with low CHADS2 scores.
In a previous study, most Japanese patients taking warfarin were treated with a target of low-intensity PT-INR(1.6-2.6)in practice, and this tendency was observed regardless of age(both B70 years and ＜70 years) 29) . Previous studies have indicated a higher baseline risk of intracranial hemorrhage in Asians compared with Caucasians, although the mechanisms were unknown 30−35) . A subanalysis of the Randomized Evaluation of Long-term Anticoagulation Therapy(RE-LY)trial demonstrated a higher incidence of major bleeding, especially intracranial hemorrhage, in Asian patients taking warfarin compared with non-Asian patients taking warfarin with similar target PT-INR (2.0-3.0) ; the one exception was Japanese patients aged B70 years with a target PT-INR of 2.0-2.6 36) . Data from other randomized clinical trials regarding NOAC versus warfarin also showed that Asian patients taking warfarin had a higher risk of bleeding compared with non-Asian patients taking warfarin 37) . Based on the results of these studies, Japanese physicians tend to empirically maintain a lower-intensity PT-INR for most NVAF patients taking warfarin. However, data from three randomized clinical trials also showed that the risk of stroke and systemic embolism is higher in Asian patients than in non-Asian patients with similar CHADS2 scores. These studies suggest that lowerintensity warfarin therapy may not provide sufficient anticoagulation for the prevention of stroke and systemic embolism 37) . The J-RHYTHM registry also reported a tendency of gradual increase in the risk of ischemic stroke／systemic embolism in patients with PT-INR scores ＜2.0 21) . Moreover, a subanalysis of the J-RHYTHM registry reported a regional difference in the International Sensitivity Index(ISI)of thromboplastin reagents (0.83-1.82)in Japan and indicated that the usage of high-ISI reagents might lead to underdosing of warfarin 38) . In our study, approximately 70％ of patients with CHADS2 scores in the range of 0-1 had low HAS-BLED scores. Based on our results, we recommend high-intensity PT-INR target range (2.00-2.99) for the prevention of stroke in patients with CHADS2 scores of 0-1 and a low bleeding risk. However, a lower intensity target may be appropriate for patients with CHADS2 scores of 0-1 who have high HAS-BLED scores, including those with risk factors such as renal dysfunction, hepatic impairment and concomitant antiplatelet drug use. To confirm these findings, a well-controlled randomized trial on low-versus high-intensity anticoagulation is needed. However, Table 4 Incidence（per patient-year）of thromboembolism and major bleeding events according to PT-INR in nonvalvular atrial fibrillation patients with a CHADS2 score of 0-1 and B65 years of age who received warfarin therapy this type of study is difficult to conduct because the incidence of both events are relatively low, and therefore a large number of subjects is needed to obtain sufficient statistical power. Alternatively, data from multicenter cohort studies focusing on Japanese NVAF patients with a low risk of stroke and bleeding are required to resolve these issues.
Limitations
There are some limitations of this study. First, the study was a retrospective observational study. We were not able to evaluate the effect and safety of different intensities of warfarin therapy, because this study was not a prospective, randomized, interventional, comparative study in NVAF patients who newly started warfarin. A total of 27.2％ of patients were censored during the study period due to problems with follow-up. We were not able to determine the diagnosis of events from the medical records review for a number of patients. The data concerning PT-INR and other clinical parameters at the time of thromboembolic and major bleeding events were not available in all the cases. Additionally, there was evidence of treatment bias, in that warfarin dose adjustment, rate and rhythm therapies for AF, and treatment of concomitant cardiovascular disease or other illnesses were determined based on the physiciansʼ judgment. Second, this was a single-center cohort study, and a large proportion of our patients had structural heart disease. Therefore, the clinical characteristics of our patients might not reflect those of general NVAF patients in Japan, because our institution is a university hospital. Moreover, the number of subjects included in our study was small, and there was a low incidence of stroke／ systemic embolisms and major bleeding. Third, we were not able to detect minor events. In practice, a physician might adjust the target intensity of anticoagulant therapy on purpose for patients who have minor events. Fourth, the number of patients with PT-INR B2.5 was small compared with patients with PT-INR ＜ 2.0, because target PT-INR values were set to be approximately 2.0�range 1.5-2.5�in our hospital. Thus, the incidence for PT-INR 2.50-2.99 and B3.00 may have been over-and underestimated.
Conclusions
Our results showed that a PT-INR of 2.00-2.99 is associated with a low incidence of both thromboembolism and major bleeding in Japanese NVAF patients aged B65 years with CHADS2 scores of 0-1.
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